Drugs / ZL-1102
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06380907 Comparator | May 2024 → Feb 2026 overdue | psoriasis | Zai Lab | Recruiting | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-26 | Crescendo Biologics Ltd. | Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis crescendobiologics.com ↗ |
| 2024-05-22 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis zailaboratory.com ↗ |
| 2021-10-21 | Crescendo Biologics Ltd. | Crescendo Biologics announces that Zai Lab has achieved proof-of-concept for ZL-1102 (Humabody®, CB001) in a Phase 1b clinical trial in psoriasis patients crescendobiologics.com ↗ |
| 2021-10-20 | Zai Lab (Shanghai) Co., Ltd. | ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study zailaboratory.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-1102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06380907 ↗ |
| Modality | Protein / enzyme biologic | “A Human VH IL-17A Antibody Fragment” NCT06380907 ↗ |
| Route | Topical | “ZL-1102 topical gel” NCT06380907 ↗ |
| Target | IL17A | “A Human VH IL-17A Antibody Fragment” NCT06380907 ↗ |